Clinical trials: CYP19
Breast Cancer
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
The purpose of this research study is to study the effects of stopping aromatase inhibitory (AI) therapy on breast cancer progression. Aromatase inhibitors are a class of drugs used to treat breast cancer in postmenopausal women.
- Trial name
- NCT00916162
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
- Trial name
- AIMSS (NCT07825454)
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Breast Cancer
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative…
- Trial name
- NCT07400523
- Testing
- Ribociclib plus aromatase inhibitor, Aromatase inhibitor
- Where
- 4 sites in China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.
Breast Neoplasms
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.
- Trial name
- NCT00437359
- Testing
- Toremifene citrate, Anastrozole
- Where
- 7 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Japan Breast Cancer Research Network
Breast Cancer Female, Osteoporosis
Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
- Trial name
- NCT04055805
- Testing
- Observational Analysis
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hypogonadism
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the…
- Trial name
- NCT01378299
- Testing
- Testosterone Cypionate
- Where
- 2 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Breast Cancer
Dendritic Cell Based Therapy for Breast Cancer Patients
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha…
- Trial name
- NCT00935558
- Testing
- DC vaccine, aromatase inhibitor
- Where
- Denmark
- Sponsor
- Inge Marie Svane
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
The objective of this study is to determine if patients taking aromatase inhibitors (AI), who are experiencing joint discomfort and stiffness, would have reduction in this discomfort and stiffness by participating in a directed…
- Trial name
- NCT02057536
- Testing
- Arm A Directed exercise program, Observation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Christiana Care Health Services
Breast Cancer, Aromatase Inhibitor
Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients
The purpose of the study was to investigate the therapeutic effect of Yoga on aromatic inhibitor-induced chronic knee pain in patients with breast cancer.
- Conditions
- Breast Cancer, Aromatase Inhibitor, Yoga, Knee Pain
- Trial name
- NCT03956875
- Testing
- yoga
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Breast Neoplasm Female, Arthralgia
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging
The goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast…
- Conditions
- Breast Neoplasm Female, Arthralgia, Aging
- Trial name
- BETA (NCT05700006)
- Testing
- Aromatase inhibitor
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- University of Michigan
Breast Cancer
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant and exemestane, anastrozole, or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells and by…
- Trial name
- NCT00688194
- Testing
- anastrozole, exemestane, fulvestrant
- Where
- Italy
- Volunteers
- 396 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
This phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT02760030
- Testing
- Fulvestrant, Laboratory Biomarker Analysis, Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00573755
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Estrogen Receptor Positive Breast Cancer, Breast Cancer
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.
- Trial name
- REVIVE (NCT01984138)
- Testing
- ESTRING, Replens, Vagifem
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Polly A. Niravath, MD
Luminal B/HER2-negative Breast Cancer
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
- Trial name
- NCT05640778
- Testing
- Dalpiciclib combined with aromatase inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors
A single--blind, randomized, placebo--controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving aromatase inhibitors as adjuvant treatment.
- Trial name
- BONADIUV (NCT02616744)
- Testing
- Ibandronic acid
- Where
- Italy
- Volunteers
- 171 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Postmenopausal Women With Advanced Breast Cancer
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy in postmenopausal patients with advanced breast cancer who received previous anti-estrogen treatment To investigate changes in blood drug…
- Trial name
- NCT00237198
- Testing
- Letrozole
- Where
- 24 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00423917
- Testing
- bevacizumab, fulvestrant
- Where
- 205 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology